Trial reportScientific reports2021
Using blood data for the differential diagnosis and prognosis of motor neuron diseases: a new dataset for machine learning applications.
Trial report in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- RES-MND: Motor neuron disease detection using Res4Net-convolutional block attention module.Turkish journal of medical sciences · 2026Article
- A neuromuscular clinician's primer on machine learning.Journal of neuromuscular diseases · 2026Review
- Duple-MONDNet: duple deep learning-based mobile net for motor neuron disease identification.Turkish journal of medical sciences · 2025Article
- Exploiting the role of CSF NfL, CHIT1, and miR-181b as potential diagnostic and prognostic biomarkers for ALS.Journal of neurology · 2024Article
- Review
- Artificial Intelligence Applications in the Diagnosis of Neuromuscular Diseases: A Narrative Review.Cureus · 2023Review
- Digital Alternative Communication for Individuals with Amyotrophic Lateral Sclerosis: What We Have.Journal of clinical medicine · 2023Review
- Prediction of in-hospital hypokalemia using machine learning and first hospitalization day records in patients with traumatic brain injury.CNS neuroscience & therapeutics · 2023Article
- Article
- Blood Analytes as Biomarkers of Mechanisms Involved in Alzheimer's Disease Progression.International journal of molecular sciences · 2022Article
- A Machine-Learning Method of Predicting Vital Capacity Plateau Value for Ventilatory Pump Failure Based on Data Mining.Healthcare (Basel, Switzerland) · 2021Article
- The Interplay Between Neuroinfections, the Immune System and Neurological Disorders: A Focus on Africa.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early differential diagnosis of several motor neuron diseases (MNDs) is extremely challenging due to the high number of overlapped symptoms. The routine clinical practice is based on clinical history and examination, usually accompanied by electrophysiological tests. However, although previous studies have demonstrated the involvement of altered metabolic pathways, biomarker-based monitoring tools are still far from being applied. In this study, we aim at characterizing and discriminating patients with involvement of both upper and lower motor neurons (i.e., amyotrophic lateral sclerosis (ALS) patients) from those with selective involvement of the lower motor neuron (LMND), by using blood data exclusively. To this end, in the last ten years, we built a database including 692 blood data and related clinical observations from 55 ALS and LMND patients. Each blood sample was described by 108 analytes. Starting from this outstanding number of features, we performed a characterization of the two groups of patients through statistical and classification analyses of blood data. Specifically, we implemented a support vector machine with recursive feature elimination (SVM-RFE) to automatically diagnose each patient into the ALS or LMND groups and to recognize whether they had a fast or slow disease progression. The classification strategy through the RFE algorithm also allowed us to reveal the most informative subset of blood analytes including novel potential biomarkers of MNDs. Our results show that we successfully devised subject-independent classifiers for the differential diagnosis and prognosis of ALS and LMND with remarkable average accuracy (up to 94%), using blood data exclusively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.